Tag : Acalabrutinib

CONFERENCE UPDATE

Acalabrutinib + BR delivers significant PFS benefit in untreated older patients with MCL: Updated analysis from the ECHO trial
Older or unfit patients with mantle cell lymphoma (MCL) often do not tolerate intensive first-line therapies due to poor tolerability. In such cases, bendamustine-rituximab (BR) combination is the most commonly used first-line regimen.1 While adding Bruton's tyrosine kinase inhibitors (BTKi), such as ibrutinib, to BR has demonstrated improved progression-free survival (PFS), this approach has not translated into an overall survival (OS) benefit, primarily due to toxicity.